PURPOSE: Differentiated thyroid carcinoma (DTC) in children and young adults is rare but often aggressive and in an advanced stage at diagnosis. In a cohort of young Belarusian patients with advanced DTC after Chernobyl we retrospectively studied parameters influencing the success of the postoperative (131)I therapy. METHODS: Included in the study were 136 patients (83 female, 53 male; median age 14.3 years, range 9.4-22.8 years) who had had total thyroidectomy in Belarus and subsequent (131)I therapy and follow-up in Germany. Of the 136 patients, 34 were classified as M1 and 102 as M0 (N0 1, N1 101). The median weight-adjusted (131)I activity administered after thyroid hormone withdrawal was 52 MBq/kg (range 24-74 MBq/kg). TNM stage, gender, administered activity, whole-body residence time and blood dose during ablation, Tg and TSH levels, date, and age at time of treatment were tested for their effect on the rate of complete remission (CR). CR was defined as a negative scan and a stimulated Tg level of <1 ng/ml at follow-up. RESULTS: CR was observed in 1 of 34 M1 and in 51 of 102 M0 patients after the first treatment. Multivariate analysis in the M0 group identified the Tg level (P < 0.0001 for log(Tg)) and the radiation absorbed dose to the blood (P < 0.001) as independent determinants; all other parameters were unimportant (P > 0.3). The regression model was able to correctly predict CR in 82 of 102 patients (80.4%). CONCLUSION: In children and young adults with advanced DTC, the rate of CR after postoperative (131)I therapy is dependent on the preablative Tg level and the radiation absorbed dose to the blood. Though the present results must be confirmed in a prospective study, they imply that preablative dosimetry may improve rates of CR.
PURPOSE: Differentiated thyroid carcinoma (DTC) in children and young adults is rare but often aggressive and in an advanced stage at diagnosis. In a cohort of young Belarusian patients with advanced DTC after Chernobyl we retrospectively studied parameters influencing the success of the postoperative (131)I therapy. METHODS: Included in the study were 136 patients (83 female, 53 male; median age 14.3 years, range 9.4-22.8 years) who had had total thyroidectomy in Belarus and subsequent (131)I therapy and follow-up in Germany. Of the 136 patients, 34 were classified as M1 and 102 as M0 (N0 1, N1 101). The median weight-adjusted (131)I activity administered after thyroid hormone withdrawal was 52 MBq/kg (range 24-74 MBq/kg). TNM stage, gender, administered activity, whole-body residence time and blood dose during ablation, Tg and TSH levels, date, and age at time of treatment were tested for their effect on the rate of complete remission (CR). CR was defined as a negative scan and a stimulated Tg level of <1 ng/ml at follow-up. RESULTS:CR was observed in 1 of 34 M1 and in 51 of 102 M0 patients after the first treatment. Multivariate analysis in the M0 group identified the Tg level (P < 0.0001 for log(Tg)) and the radiation absorbed dose to the blood (P < 0.001) as independent determinants; all other parameters were unimportant (P > 0.3). The regression model was able to correctly predict CR in 82 of 102 patients (80.4%). CONCLUSION: In children and young adults with advanced DTC, the rate of CR after postoperative (131)I therapy is dependent on the preablative Tg level and the radiation absorbed dose to the blood. Though the present results must be confirmed in a prospective study, they imply that preablative dosimetry may improve rates of CR.
Authors: Frederik A Verburg; Bart de Keizer; Cornelis J M Lips; Pierre M J Zelissen; John M H de Klerk Journal: Eur J Endocrinol Date: 2005-01 Impact factor: 6.664
Authors: Heribert Hänscheid; Michael Lassmann; Markus Luster; Stephen R Thomas; Furio Pacini; Claudia Ceccarelli; Paul W Ladenson; Richard L Wahl; Martin Schlumberger; Marcel Ricard; Al Driedger; Richard T Kloos; Steven I Sherman; Bryan R Haugen; Vincent Carriere; Carine Corone; Christoph Reiners Journal: J Nucl Med Date: 2006-04 Impact factor: 10.057
Authors: Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner Journal: World J Surg Date: 2002-05-21 Impact factor: 3.352
Authors: Heribert Hänscheid; Michael Lassmann; Markus Luster; Richard T Kloos; Christoph Reiners Journal: Endocr Relat Cancer Date: 2009-07-23 Impact factor: 5.678
Authors: Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-29 Impact factor: 9.236
Authors: Yuri E Demidchik; Eugene P Demidchik; Christoph Reiners; Johannes Biko; Mariko Mine; Vladimir A Saenko; Shunichi Yamashita Journal: Ann Surg Date: 2006-04 Impact factor: 12.969
Authors: Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita Journal: Thyroid Date: 2015-07 Impact factor: 6.568
Authors: Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg Journal: Nat Rev Endocrinol Date: 2011-08-09 Impact factor: 43.330
Authors: Frederik A Verburg; Uwe Mäder; Markus Luster; Heribert Hänscheid; Christoph Reiners Journal: Eur J Nucl Med Mol Imaging Date: 2015-06-13 Impact factor: 9.236